See more : PTT Public Company Limited (PTT-R.BK) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Emaar The Economic City (4220.SR) Income Statement Analysis – Financial Results
- SK Networks Company Limited (001740.KS) Income Statement Analysis – Financial Results
- IC Enterra Yenilenebilir Enerji A.S. (ENTRA.IS) Income Statement Analysis – Financial Results
- Haffner Energy S.A. (ALHAF.PA) Income Statement Analysis – Financial Results
- Oil-Dri Corporation of America (ODC) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
| Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
| Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
| Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
| Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
| Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
| Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
| EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
| EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
| Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
| Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
| Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
| Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
| Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
| Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
| Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
| Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
| EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
| Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific
PPD Named ‘Best Vaccine CRO of the Year' in Asia-Pacific
PPD Wins Multiple Awards at Clinical Researcher of the Year Competition
PPD Wins Multiple Awards at Clinical Researcher of the Year Competition
PPD, Inc. (PPD) CEO David Simmons on Q3 2021 Results - Earnings Call Transcript
PPD, Inc. (PPD) Tops Q3 Earnings and Revenue Estimates
PPD Reports Third Quarter and Year-To-Date 2021 Results
PPD Reports Third Quarter and Year-To-Date 2021 Results
Medable Secures $304 Million in Funding at $2.1 Billion Valuation; New Round Co-Led by Blackstone Growth, GSR Ventures and Tiger Global
PPD Named Clinical Research Company of the Year for Second Consecutive Year
Source: https://incomestatements.info
Category: Stock Reports